UBS Maintains a 'Buy' on Celgene (CELG); Tough Scenario, but NPV Still Supportive
Get Alerts CELG Hot Sheet
Price: $108.24 --0%
Rating Summary:
7 Buy, 27 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Rating Summary:
7 Buy, 27 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
UBS maintains a 'Buy' on Celgene (NASDAQ: CELG) price target of $78.00 (from $85.00).
Analyst, Matthew Roden, said, "We are lowering Revlimid numbers as we remove EU maintenance from our model, as we are skeptical of near-mid term approval in this setting. However, we see clearly favorable riskreward in CELG shares overall at these levels given (1) very low expectations for near term apremilast data, (2) lower risk to accelerated approval of pomalidomide, and upside to pom fore casts (UBSe 2015 $712m vs. cons $360m), and (3) upside to Revlimid front-line market share through use of CRd (carfilzomib-Revlimid-dex) after impressive ASCO complete response data."
For UBS, the current multiple implies limited downside from here, and notes the company's growth profile. CELG is now trading at 10.8c UBS's new 2013 PES ($5.52 from $5.58), despite its 23% 4-yr EPS CAGR, which UBS analyst finds attractive relative to biotech comps and the pharma group (13x and 12x)
For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.
Shares of Celgene closed at $59.45 yesterday.
Analyst, Matthew Roden, said, "We are lowering Revlimid numbers as we remove EU maintenance from our model, as we are skeptical of near-mid term approval in this setting. However, we see clearly favorable riskreward in CELG shares overall at these levels given (1) very low expectations for near term apremilast data, (2) lower risk to accelerated approval of pomalidomide, and upside to pom fore casts (UBSe 2015 $712m vs. cons $360m), and (3) upside to Revlimid front-line market share through use of CRd (carfilzomib-Revlimid-dex) after impressive ASCO complete response data."
For UBS, the current multiple implies limited downside from here, and notes the company's growth profile. CELG is now trading at 10.8c UBS's new 2013 PES ($5.52 from $5.58), despite its 23% 4-yr EPS CAGR, which UBS analyst finds attractive relative to biotech comps and the pharma group (13x and 12x)
For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.
Shares of Celgene closed at $59.45 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teleperformance (TEP:FP) (TLPFY) PT Lowered to EUR125 at RBC Capital, 'perceived risk profile makes it a no-fly zone for many investors'
- Archrock (AROC) PT Raised to $21 at RBC Capital
- BofA Securities Upgrades Estee Lauder (EL) to Buy; 'Earnings have bottomed'
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!